Skip to main content
Clinical Trials/NCT03634839
NCT03634839CompletedPhase 1

Effects of E-cigarette Flavors on Youth

Yale University1 site in 1 country42 target enrollmentStarted: November 7, 2022Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Completed
Enrollment
42
Locations
1
Primary Endpoint
Liking: Difference Score in Liking/Wanting of Each E-cigarette Condition

Study Overview

Brief Summary

This study is an examination of the influence of sweet and cooling flavors on the appeal and abuse potential of nicotine-containing e-cigarettes among susceptible youth.

Detailed Description

Researchers will examine the influence of sweet and cooling flavors on the appeal and abuse potential of nicotine-containing e-cigarettes among susceptible youth. Participants will rate the flavor intensity, coolness, sweetness, and irritation experienced using validated rating scales. Forty youth (18-20 years of age) who have experience with e-cigarettes and will participate in 1 laboratory session. They will receive 1 nicotine concentrations (36mg/ml nicotine salt) during the session; during the session they will be exposed, in random order, to sweet (watermelon) and sweet-cooling (watermelon-menthol) flavors combined with the assigned session nicotine concentration.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Other
Masking
Triple (Participant, Care Provider, Investigator)

Masking Description

Flavor and nicotine concentration is blinded to participant. Research staff and investigators are blinded to flavor order administer to participants.

Eligibility Criteria

Ages
18 Years to 20 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Ages 18-20 years
  • Able to read and write
  • Used e-cigs at least 10 times in lifetime
  • Used e-cigs in past 30 days

Exclusion Criteria

  • Current use of non-prescription substances besides nicotine, marijuana, alcohol
  • Any significant current medical or psychiatric condition
  • Known hypersensitivity to propylene glycol
  • Pregnant or lactating females
  • Uncontrolled asthma
  • Nut/e-liquid flavorant allergy
  • current marijuana (tetrahydrocannabinol) vaping + E-cigarette or vaping use Associated Lung Injury (EVALI) symptoms

Arms & Interventions

Sweet non-menthol, nicotine 36mg/ml

Experimental

Sweet flavor non-menthol (Watermelon) with 36mg/ml Nicotine

Intervention: Flavoring Agents (Drug)

Sweet non-menthol, nicotine 36mg/ml

Experimental

Sweet flavor non-menthol (Watermelon) with 36mg/ml Nicotine

Intervention: Nicotine (Drug)

Sweet menthol, nicotine 36mg/ml

Experimental

Sweet flavor with menthol (Watermelon-menthol) with 36mg/ml Nicotine

Intervention: Flavoring Agents (Drug)

Sweet menthol, nicotine 36mg/ml

Experimental

Sweet flavor with menthol (Watermelon-menthol) with 36mg/ml Nicotine

Intervention: Nicotine (Drug)

Outcomes

Primary Outcomes

Liking: Difference Score in Liking/Wanting of Each E-cigarette Condition

Time Frame: Following administration of e-cigarette condition 1 (+10 minutes), following administration of e-cigarette condition 2 (+40)

The Labeled Hedonic Scale will be used to ask about liking and wanting of the e-cigarette (one item Visual Analog Scale with ratings ranging from "most disliked sensation imaginable" to "most liked sensation imaginable" with higher values indicating greater liking). Specific scale semantic structure and corresponding values: most disliked imaginable=-100, dislike extremely=-62.9, dislike very much=-41.6, dislike moderately=-17.6, dislike slightly=-5.9, neutral=0, like slightly=6.3, like moderately=17.8, like very much=44.4, like extremely=65.7, most liked imaginable=100.

Irritation/Harshness: Difference Score in Irritation of Harshness of Each E-cigarette Condition

Time Frame: Following administration of e-cigarette condition 1 (+10 minutes), following administration of e-cigarette condition 2 (+40)

Difference in irritation at each e-cigarette condition as measured by the computerized Generalized Labeled Magnitude Scale (gLMS). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. The Generalized Labeled Magnitude Scales (gLMS) are category ratio scales with seven semantic labels: "no sensation", "barely detectable", "weak", "moderate", "strong", "very strong", and "strongest imaginable", positioned quasi-logarithmically as per empirically determined semantic magnitudes on a 0-100 scale (strongest imaginable at the 100 end).

Reinforcing Efficacy: Difference Score in Drug Effects of Each E-cigarette Condition

Time Frame: Following administration of e-cigarette condition 1 (+10 minutes), following administration of e-cigarette condition 2 (+40)

Difference between e-cigarette effects for each e-cigarette condition as measured by the computerized version of the Drug Effects Questionnaire (DEQ). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. A modified version of the Drug Effects Questionnaire (DEQ) will be used in which participants rate acute responses to the e-cigarette on a 0-100mm scale from "not at all" (0mm) to "extremely" (100mm). Higher values indicate stronger reinforcing efficacy (i.e., wanting/liking effects).

Craving: Change in Craving Score for E-cigarette

Time Frame: At baseline (+0 minutes), Following administration of e-cigarette condition 1 (+10 minutes), following administration of e-cigarette condition 2 (+40)

Difference from baseline in craving for each e-cigarette condition will be measured by the Generalized Labeled Magnitude Scale (gLMS). Participants will self-report their craving for e-cigarettes using a computer mouse to indicate where on the scale response falls. The Generalized Labeled Magnitude Scales (gLMS) are category ratio scales with seven semantic labels: "no sensation", "barely detectable", "weak", "moderate", "strong", "very strong", and "strongest imaginable", positioned quasi-logarithmically as per empirically determined semantic magnitudes on a 0-100 scale (strongest imaginable at the 100 end).

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials